HCDR3 definition

HCDR3 means the third heavy chain complementarity-determinant region determined by the amino acid sequence of the variable (V) domain that is flanked by the invariant cysteine 104 and the invariant tryptophan 118 according to the IMGT system of numbering (as set forth at ▇▇▇▇://▇▇▇.▇▇▇▇.▇▇▇/IMGTScientificChart/Nomenclature/IMGT-FRCDRdefinition.html) corresponding to cysteine 92 and tryptophan 103 in the ▇▇▇▇▇ system and cysteine 92 and tryptophan 103 of the Chothia system.
View Source
HCDR3 means the third heavy chain complementarity-determinant region determined by the amino acid sequence of the variable (V) domain [*].
View Source

Examples of HCDR3 in a sentence

  • If Merus has granted rights to such General Monoclonal Antibody to a Third Party, Incyte may (but shall not be required to) request that Merus create a monoclonal Antibody that is less than [**] homologous in HCDR3 to such General Monoclonal Antibody and subsequently deem such modified General Monoclonal Antibody a Selected Monoclonal Antibody under such Program.

  • The IGHV, IGHD, and IGHJ genes and the HCDR3 amino acid sequences expressed in the leukemic cells of 26 CLL patients tested for VLR39 reactivity are shown.

  • The CT , ΔCT, and Δ(ΔCT) of the qPCR reaction using the CLL donor HCDR3-specific probe and GAPDH probes were used to calculate the fold change in the CLL donor HCDR3 transcript relative to the GAPDH endogenous control.

  • If Merus has granted rights to such General Monoclonal Antibody to a Third Party, Incyte may (but shall not be required to) request that Merus create a monoclonal Antibody that is less than [*] homologous in HCDR3 to such General Monoclonal Antibody and subsequently deem such modified General Monoclonal Antibody a Selected Monoclonal Antibody under such Program.

  • Detection of CLL recurrence by quantitative real-time PCR Months After End of CFAR Treatment Donor CLL HCDR3 (CT ) GAPDH (CT) ΔCT Δ(ΔCT) Fold Change CLL HCDR3 Detection 38 not detectable 18.7 ± 0.1 0.00 0 0 negative 51 37.48 25.4 ± 0.4 12.10 2.02 0.25 weak positive 56 26.4 ± 0.1 18.4 ± 0.2 8.02 -2.02 4.05 positive Table S2: Detection of CLL recurrence by quantitative real-time PCR.

  • Cryopreserved MNCs from the CLL donor after treatment were analyzed by qPCR for the presence of CLL donor HCDR3 transcript.